A single group treatment, phase 4, study to assess the effect of 1 dose with oxymetazoline nasal spray(Otrivin®) on physical capacity of males and females aged 18 and 64 years suffering from Chronic Obstructive Pulmonary Disease (COPD)

Status

Not yet recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-520177-12-00

Enrollment

Registered

2025-01-24

Start date

Unknown

Completion date

Unknown

Last updated

2025-01-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Plumonary Disease (COPD)

Brief summary

walking distance

Detailed description

Borg scale

Interventions

DRUGNasolin 1 mg/ml nenäsumute

DRUGliuos

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
walking distance	—

Secondary

Measure	Time frame
Borg scale	—

Countries

Norway

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026